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Abstract 
Background: Optimizing the measurement of Continuous Positive Airway Pressure 
(CPAP) compliance and treatment efficacy is paramount for patients with obstructive 
sleep apnea syndrome (OSAS). Compliance knowledge is currently based on data 
coming from CPAP machines; however algorithms and measured parameters vary from 
one machine to another. This study was conducted to clinically evaluate a novel device, 
NOWAPI®, designed to assess compliance remotely in conjunction with any CPAP 
machine. NOWAPI® was tested against polygraphy, the gold standard for the measure-
ment of CPAP treatment duration and residual apnea-hypopnea index (AHI).
Methods: Single group assignment, open label, non-randomized. Sleep laboratory 
setting. 22 adult patients with OSAS treated by CPAP were included. Recordings were 
performed during one night while the patient was treated with his/her usual CPAP and 
interface. NOWAPI® data were collected electronically and compared to data acquisition 
and visual scoring using an EMBLETTA® GOLD polygraph. Statistics were only descriptive.
Results: Recordings were performed with six different CPAP machines and three dif-
ferent interfaces (full facemask, nasal pillow, nasal mask). The median [Q1; Q3] absolute 
difference in CPAP treatment duration between NOWAPI® and polygraphy was of 
1.0 min [0.0; 12.0], corresponding to a relative difference of 0.21 % [0.0; 2.2] (Per Protocol 
data set, n = 20). NOWAPI® tended to underestimate residual AHI in a magnitude of 
two events per hour as compared to polygraphy. The device was well tolerated and the 
patient satisfaction was good.
Conclusions: This clinical study confirmed prior bench tests, showing that NOWAPI® 
estimate of CPAP treatment duration was clinically acceptable and in agreement 
with polygraphy. Although a limited number of OSAS patients treated by CPAP were 
included, relevant findings for the device improvement were identified.
Trial Registration ClinicalTrials.gov identifier: NCT01441622. The study was funded by Air 
Liquide HealthCare
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Background
Sleep apnea syndrome (OSAS) has a high prevalence and has serious consequences on 
public health with high costs for diagnosis and treatments [1–3]. It is associated with an 
increased risk of accidents and cardiovascular comorbidities [4, 5]. The standard treat-
ment for OSAS is Continuous Positive Airway Pressure (CPAP) which improves the 
quality of sleep and alertness and decreases the associated risks. A minimum of 3–4 h of 
treatment every night is necessary to obtain long term benefit [6, 7]. In several European 
countries, this minimum compliance has been proposed as a “cut-off” minimum limit 
per night by payers for reimbursement of CPAP [2, 7]. Furthermore, remote monitoring 
was shown beneficial to CPAP compliance [8].
Compliance is currently assessed on CPAP outputs with algorithms varying from one 
model to the other such that there is no standardization of data. The NOWAPI® medi-
cal device (Fig. 1) has been designed to remotely monitor duration of CPAP use, residual 
number of apneas and hypopneas, leaks and delivered pressure, whatever the machine 
used. The device is connected to the breathing circuit at the CPAP output. It uses a tun-
nel with area changes for measuring instantaneous pressure and flow rate inside the 
patient circuit (Fig.  2). The technology is especially designed for the detection of pre-
cise flow variations and the identification of breathing cycles. The device was shaped to 
detect these variations without affecting the treatment (very low pressure losses). Identi-
fication of apneas and hypopneas is based on consensual definitions: an apnea is defined 
as a 10 s event with a tidal volume less than 20 % of the patient reference tidal volume; 
a hypopnea is defined as a 10 s event with a tidal volume between 20 and 50 % of the 
patient reference tidal volume. The device can store 1 month of data in the absence of 
electrical power, and up to 1 year if plugged in. The information can then be transmit-
ted by GSM/GPRS on a daily basis or recovered by connecting the device directly to a 
computer.
The device was previously validated in a bench test simulating OSA patients [9]. Tests 
concluded that NOWAPI® did not influence the CPAP treatment (no pressure drop) and 
presented a good performance for detecting the treatment duration (never higher than 
3 min over a 4-hr test) and residual events (no significant differences in AHI estimates 
Fig. 1 NOWAPI® stands on the patient circuit, at the output of the CPAP device. The diode indicator gives a 
traffic light feedback to the patient on the previous night CPAP treatment duration
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against CPAPs). This clinical study was conducted to further evaluate the performance 
of the NOWAPI® in closest to real conditions of use, against independent measurements 
during lab polygraphy. This exploratory study was designed as solely descriptive and 
included a sample of 22 patients treated for OSAS.
Methods
Study design
The study was single centre, one group, non randomised open exploratory study. Eli-
gible patients were adults with predominantly obstructive OSAS (>50 % of obstructive 
events), meeting CPAP treatment criteria, treated for at least 2 months and requiring an 
in-hospital night respiratory polygraphic recording. It was planned to enroll at least 10 
patients or more with a residual AHI above 10 per hour of sleep, based on the last home 
provider report available. Patients were non eligible if they had chronic respiratory dis-
ease, acute rhinitis, rhinopharyngitis, moderate to severe chronic heart failure, Cheyne-
Stokes respiration, not under control progressive illness which could interfere with study 
procedures.
The study protocol was approved by an Independent local Ethics Committee and by 
the French Drug Agency. The study was performed in accordance with Good Clinical 
Practice guidelines. All patients gave their informed consent before initiation of any 
measures specific to the study.
In order to test the NOWAPI® performance in various and random situations, evalua-
tions were performed in usual conditions of a nocturnal respiratory polygraphy record-
ing in the sleep lab, with the usual patient’s equipment including his CPAP device, 
interface and in some cases humidifier. Patients were equipped in the evening and were 
given a sleep agenda and a satisfaction questionnaire. In the morning, the equipment 
was removed and questionnaires were collected. All events which occurred overnight 
that might have interfered with the recordings were reported.
Data collection
Duration of CPAP treatment, number of apneas and hypopneas and mean positive 
pressure measured by NOWAPI® were compared to those measured by respiratory 
polygraphy (Embletta GOLD®, ResMed), routinely used for the diagnosis and severity 
evaluation of OSAS conjointly with clinical sleep evaluation [10].
Fig. 2 Schematic view of the NOWAPI®. DA and DB diameter upstream and at restriction site, respectively. 
Patm atmospheric pressure sensor, Pups pressure sensor upstream of the restriction, Pres pressure sensor at 
restriction site
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The two different files the NOWAPI® stores were collected: the summary data file of 
mean values recorded by consecutive 15-min periods and the detailed data file including 
the data recorded every 40 ms.
The investigator estimated CPAP treatment duration and the numbers of apneas and 
hypopneas on the same 15-min recording periods as the NOWAPI® during the record-
ing night and reported them on the Case Report Form. Visual scoring of apneas and 
hypopneas from respiratory polygraphic data was performed according to AASM 2007 
guidelines [11].
Patient opinion on NOWAPI® was evaluated through a self-administered question-
naire. It was divided in two parts: the general aspect of the device (three questions) and 
the light-emitting diode (two questions). Answers were given using a satisfaction scale 
(0, 20, 40, 60, 80, 100 %), 0 % being the poorest satisfaction and 100 % the maximum.
Sleep was evaluated by the patient through a sleep-log, which was used to calculate 
subjective total sleep time (TST), sleep onset latency (SOL), wake after sleep onset 
(WASO) and time in bed (TIB).
Statistical analysis
All statistical results of this study were exploratory and exclusively descriptive. This 
study was purely exploratory and a pragmatic approach had been chosen to estimate its 
sample size. As no assumption could be made prior to the start of the study on the pri-
mary efficacy criterion, no sample size calculation could be performed. Thus, the num-
ber of evaluable patients chosen was 20. This was expected to be sufficient to establish 
preliminary descriptive conclusions regarding NOWAPI® performance in estimating the 
duration of CPAP treatment. An “evaluable” patient was a patient with a record dura-
tion ≥240 min for both NOWAPI® and polygraph.
The primary analysis consisted in assessing the absolute difference in CPAP treatment 
durations estimated by NOWAPI® and by respiratory polygraphy, in the Per Protocol 
Set (PPS), i.e. all evaluable patients. The CPAP treatment duration estimated by the 
NOWAPI® during the recording night was obtained by summing all CPAP treatment 
durations estimated during all 15-min recording periods of the recording night. The 
overnight CPAP treatment duration was selected as the primary variable rather than the 
15-min values as this is the quantitative indicator of patient observance communicated 
to the physician.
The mean of absolute differences (absolute value of differences) between the number 
of apnoeas and hypopneas estimated by the NOWAPI® and estimated by the investiga-
tor from polygraphic data were calculated for each of the 15-min periods included in 
the recording night and overall (over all the 15-min periods of recording included in the 
recording night). The 15-min values are more of interest from an engineering point of 
view to determine the accuracy of NOWAPI® whether the overall value is a quantitative 
indicator of CPAP treatment quality communicated to the physician.
A post hoc analysis was performed on a patient subgroup for which detailed 
NOWAPI® data files were available.
Statistical analyses were performed using SAS® Software, version 9.2. (SAS Institute, 
North Carolina, USA).
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Results
Patients were mainly men (18/22), aged 61 ± 13 years and with BMI of 29.6 ± 4.5 kg/
m2 (mean ± SD). Their baseline characteristics are outlined in Table 1. Reasons for the 
in-hospital night respiratory polygraphic recording were: unrefreshing sleep (10/22), 
recurrent awakenings (8/22), disturbed sleep (5/22), excessive daytime sleepiness (5/22), 
poor compliance to CPAP treatment (2/22) and residual AHI >20/h (1/22). From avail-
able prior home CPAP reports (n = 21), residual AHI was 5.8 ± 5.5/hr and in only three 
patients was ≥10/hr, whereas 10 such patients were requested per protocol. Two patients 
with major protocol deviations (less than 4 h of respiratory polygraphic recordings, i.e. 
0 and 2.25 h respectively) were not included in the main analysis. Interfaces included 12 
face masks, 8 nasal masks and 2 nasal pillows. 20 patients had an auto-adjusting CPAP 
device and two had a conventional CPAP device. 6 different CPAP devices were used [S8 
AutoSet Spirit™ II (ResMed), S9 AutoSet™ (ResMed), REMstar Auto A-Flex™ PR One 
(Philips Respironics), REMstar Auto M Series with A-Flex (Philips Respironics), GoodK-
night® 420 (Tyco healthcare), KXS-Bump (Kaerys)]. Fourteen patients had a humidifier 
and eight none. Four patients rose from bed and three patients removed their interface 
during the recording night.
Considering the overall recording night, the median CPAP treatment duration esti-
mated by NOWAPI® and from polygraphy was of 471  min (ranging from 11 to 570) 
and 479 min (ranging from 405 to 585), respectively (PPS). The median [Q1; Q3] abso-
lute difference in CPAP treatment duration between NOWAPI® and polygraphy was of 
1.0  min [0.0; 12.0], corresponding to a relative absolute difference of 0.21  % [0.0; 2.2] 
(PPS). The maximum absolute difference was of 439 min (97.6 % in relative absolute dif-
ference). Figure 3 presents for each patient the CPAP treatment duration measured by 
NOWAPI® against the one measured by polygraphy. It shows that NOWAPI® measured 
the exact same treatment duration as polygraphy in all but four patients.
Examination of NOWAPI® detailed data files was conducted to further analyze the 
CPAP treatment duration results and in particular the outliers. Detailed data files were 
available in only 18 of the 20 patients of the PPS. An example of NOWAPI® detailed 
data is shown in Fig. 4: flow rate determination (i.e. treatment detection) is allowed by 
Table 1 Characteristics of the study population (full analysis set, n = 22)
Time since OSAS diagnosis is expressed in median [Q1–Q3]. All other values are normally distributed and expressed as 
mean ± SD
OSAS obstructive sleep apnea syndrome, CPAP continuous positive airway pressure, Q1 first quartile, Q3 third quartile
Age (years) 61 ± 13
Gender (% male) 82 %
Body mass index (kg/m2) 29.6 ± 4.48
Neck circumference (cm) 40.6 ± 3.8
Waist circumference (cm) 106.5 ± 13.5
Time since OSAS diagnosis (years) 3.2 [0.5–5.3]
Epworth scale score at diagnosis 11.8 ± 4.0
Polygraphic data at diagnosis
 Apnoea-hypopnoea index (/hr) 43.0 ± 16.6
 Number of obstructive events (/hr) 28.9 ± 16.9
Mean nightly CPAP use (hrs) in the month prior selection 5.5 ± 2.2
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calculating the difference between the two pressure signals (pink and blue curves). If 
this difference (yellow curve) varies, it means that there is a flow rate, like what is seen 
in patient #20. In patient #19, the two pressure signals are always superimposed: this 
finding is compatible only with two situations, either no flow rate in the patient cir-
cuit, either reverse connection of the NOWAPI® on the patient circuit. Review of the 
18 NOWAPI® detailed data files showed no variation in differential pressure (indicating 
with high probability the reverse connection of the NOWAPI® on the patient circuit, gas 
flow in the wrong sense through the device, during the recording night) in the 4 outlier 
Fig. 3 Comparison of overnight CPAP treatment duration (minutes)—Respiratory Polygraph vs NOWAPI® 
(PP data set, n = 20). Crosses represent the 16 patients with a perfect agreement in CPAP treatment duration 
measurement between NOWAPI® and polygraphy, all crosses being aligned on the 1:1 fit line. The circles 
represent the four outliers. Detailed NOWAPI® data files of patients #19 and 20 are presented in Fig. 4
Fig. 4 Example of NOWAPI® detailed data in two typical patients. The device measures two pressure signals 
(upstream restriction and at the site of restriction, pink and blue curves, left y-axis). Variations in the difference 
between two pressures (differential pressure, yellow curve, right y-axis) indicate a flow rate is detected. Panel a 
shows detailed data in patient #20, with variation in differential pressure indicating detection of a flow rate in 
the patient circuit, i.e. a CPAP treatment. Panel b shows detailed data in patient #19. The two pressure signals 
are always superimposed, there is no variation in differential pressure. This finding is compatible only with 
two situations, either no flow rate in the patient circuit, either reverse connection
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patients. NOWAPI®detailed data files of all other 14 patients showed the expected vari-
ation in differential pressure.
A post hoc analysis was therefore conducted on the 14 patients having a detailed data 
file indicating correct connection: Considering the overall recording night, the median 
CPAP treatment duration estimated by NOWAPI® and from respiratory polygra-
phy was of 478 min (ranging from 405 to 570) and 479 min (ranging from 405 to 585), 
respectively. Median [Q1; Q3] absolute difference in CPAP treatment duration between 
NOWAPI® and respiratory polygraphy was of 0.0 min [0.0; 1.0], corresponding to a rela-
tive difference of 0.0 % [0.0; 0.24] overall on the recording night for this subgroup. The 
maximum absolute difference was of 15 min (2.6 % in relative difference).
Evaluation of the performance of the NOWAPI® in apnea and hypopnea detection was 
therefore conducted only in patients for whom NOWAPI® detailed data file examina-
tion indicated a correct device connection. Differences between numbers of apneas and 
hypopneas estimated by NOWAPI® and from polygraphic data interpretation are pre-
sented for each of the common 15-min recordings in Fig. 5 (panels A, B and C). Agree-
ment between NOWAPI® and polygraphy was within two apneas or less in most records 
(427/452, i.e. 94 %), and similarly within two hypopneas or less in most records (408/452, 
i.e. 90 %). Underestimation of more than two respiratory events par NOWAPI® (20/452 
and 37/452 of records in apnea and hypopnea detection respectively) was most frequent 
than overestimation of more than two respiratory events (5/452 and 7/452 of records 
in apnea and hypopnea detection respectively). Considering the overall recording 
night, the median [Q1; Q3] absolute difference in AHI was 2.2 [1.1; 3.4] events per hour 
between NOWAPI® and polygraphy. Figure 5 (Panel D) shows residual AHIs measured 
Fig. 5 Differences between numbers of apneas and hypopnoeas (Panel a), apneas (Panel b) and hypopneas 
(Panel c) estimated by NOWAPI® and by respiratory polygraphy are presented for each of the common 
15-min periods (n = 452) of the recording night. The x-axis plots the difference [NOWAPI® minus Respiratory 
Polygraph] and the y-axis the number of records. Panel d presents the Apnea-Hypopnea Index (events per 
hour) by patient for the overall recording night, estimated by NOWAPI® plotted against polygraphy with a 1:1 
fit line. PP data set with detailed NOWAPI® data files indicating correct connection (n = 14)
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by NOWAPI® plotted against respiratory polygraphic data interpretation for the 14 
patients overall on the recording night, and confirmed NOWAPI® underestimation of 
residual respiratory events, in an order of magnitude of about two events per hour.
From the sleep agenda, TST was 433.0  ±  105.8  min (around 7.2  h), SOL was 
32.8 ± 27.8 min, WASO was 34.4 ± 49.5 min and TIB was 501.9 ± 51.2 min (around 
8.3 h) (n = 22) (mean ± SD).
Figure 6 shows patient opinion on NOWAPI®. Patients were globally highly satisfied 
of the design of the device (shape, size, color). Diode indicator, included to provide feed-
back to the patient on his compliance, obtained the lowest satisfaction rating. No patient 
reported that the traffic light indicator was very helpful (100 % rating) in indicating the 
quality of the treatment and 42 % of patients reported that it was not helpful at all (0 % 
rating). Conversely, the patients quite high-rated disturbance during the night, 8  % of 
patients having reported high disturbance (100 % rating) and 17 % of patients reported 
no disturbance (0 % rating).
No adverse event was reported during the study.
Discussion
Our study shows that, when correctly connected, NOWAPI® can reliably measure CPAP 
treatment duration versus respiratory polygraphy, independently of the mask or the 
CPAP applied, either conventional or auto-CPAPs. Following the bench tests, the study 
aimed to evaluate the clinical feasibility and accuracy of this new device in a small group 
of patients treated by different CPAPs and interfaces. We used respiratory polygraphy as 
a reference to assess NOWAPI® reliability as recommended in consensus guidelines for 
the diagnosis and monitoring of OSAS in adults [10]. Respiratory polygraphy is indeed 
regularly used under the supervision of qualified sleep technicians for the follow-up of 
patients with OSAS who have been diagnosed and treated for several months.
Treatment duration is a key parameter for the long-term assessment of patients with 
OSAS treated at home by CPAP, because duration is strongly associated with effec-
tiveness of CPAP therapy. NOWAPI® defines a treatment period by a period during 
which both a positive pressure and a patient breathing are detected. Most of the cur-
rent CPAP devices accurately measure CPAP treatment duration, as it is the operating 
Fig. 6 Patients’ opinion on NOWAPI® (n = 12). Results are mean ± SD. The self-administered satisfaction 
questionnaire included three questions on the general aspect of the device and two questions on the light 
indicator. Answers were given using a satisfaction scale (0, 20, 40, 60, 80, 100 %), 0 % being the poorest satis-
faction and 100 % the maximum
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time of the devices. From respiratory polygraphic data, the investigator was also able 
to estimate accurately the CPAP treatment duration, although this is not a usual assess-
ment, especially in specific predetermined 15-min periods. The results of this clinical 
study provided a necessary further assessment of the NOWAPI® performance than the 
one provided by the bench tests. The bench test [9] indicated a difference in treatment 
duration never higher than 3 min (1.25 % in percentage time difference) and never lower 
than 1 min (−0.42 % in percentage time difference). Our study showed that NOWAPI® 
measured the exact same CPAP treatment duration than polygraphy in 16/20 patients 
and underestimated the duration in the remaining 4, sometimes remarkably (almost 
no treatment detection in one patient) (Fig.  3). In those four patients, analysis of the 
NOWAPI® detailed data files indicated reverse connection of the NOWAPI® during the 
recording night, a possibility that could not have been detected by a bench test and was 
not anticipated because NOWAPI® has two different ends (one male and one female). 
It is of important note that even with a misconnected NOWAPI®, the positive pressure 
was properly administered because the NOWAPI® measures flow not using a pneumot-
achograph but with a customized design that minimizes pressure drops (Fig. 2).
Residual (i.e. under CPAP treatment) AHI is also an important parameter to monitor 
in patients with OSAS because it is an indicator of quality of the treatment: an AHI lower 
than 10 should be achieved with appropriate CPAP settings and interface. The bench test 
[9] indicated an AHI difference of 0.9 ±  1.6 events per hour between NOWAPI® and 
the bench actual values. The clinical study showed that agreement between NOWAPI® 
and respiratory polygraphy was within two apneas or less in 94 % of all 15-min records 
(Fig. 5b) and within two hypopneas or less in 90 % of all 15-min records (Fig. 5c). When 
summing all differences over the recording night, it appeared that NOWAPI® mainly 
underestimated AHI (in 12/14 patients, Fig. 5d), the median absolute difference being 
of 2.2 events per hour. Having a difference in apnea and hypopnea scoring between 
NOWAPI® and respiratory polygraphic interpretation was expected, as the scoring 
methods differ. NOWAPI® defines an apnea with a decrease of 80 % or more of the tidal 
volume that lasts at least 10 s and an hypopnea if there is a decrease of 50 % or more of 
the tidal volume that lasts at least 10 s. According to published guidelines for respira-
tory polygraphic interpretation [11], (i) an apnea is scored when there is a reduction of 
at least 90 % of the flow signal from baseline, lasting at least 10 s (the decrease in flow 
should be present during at least 90 % of the total event duration) and (ii) a hypopnea is 
scored when there is a reduction of at least 30 % of the flow signal from baseline, lasting 
at least 10 s (the decrease in flow should be present during at least 90 % of the total event 
duration), and associated with an arterial desaturation of 3 % or more. However, main 
objective of the long-term home monitoring of CPAP treatment is not to precisely meas-
ure AHI but to detect the patients with high residual event rates, i.e. those requiring a 
CPAP treatment adjustment (settings, interface,…). One main study result is that AHI 
underestimation by NOWAPI® would have resulted in missing to detect two patients 
with residual AHI ≥10/hr (with polygraph) and requiring treatment adjustment.
Patient satisfaction regarding the general aspect of the device was good (Fig. 6). How-
ever, low satisfaction regarding the traffic-light indicator (helpfulness and light distur-
bance) was not expected. It will require deeper understanding of the patients’ needs and 
wishes in term of CPAP treatment feedback.
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The main limitation of the present study is the small number of patients. However, 
the study was exploratory and was not designed to demonstrate statistical equivalence 
with ventilatory polygraphy. Sample size was not estimated and 20 evaluable patients 
were anticipated enough for this pilot study of first use in OSAS patients. Indeed, even 
with the limited number of patients, the study allowed to identify that misconnection 
was possible despite the two different NOWAPI® ends, a useful information before a 
wider use. Second, the study allowed testing the novel device with six frequently used 
CPAP machines, the three available interfaces and with/without humidifier. Third, the 
study showed that NOWAPI® tended to underestimate AHI, and this was not identi-
fied by the bench tests. Underestimation might not be the best option if the main aim of 
remote monitoring is to detect patients with high residual events in which CPAP treat-
ment needs adjustment. Another limitation is that although it was planned to include 
10 patients with a residual AHI of 10 or above, only three were included. This limits the 
conclusions that can be made on the NOWAPI® performance in detecting patients with 
high residual events, but reflects the real life situation, i.e. that very few patients have a 
high residual AHI under CPAP treatment.
Conclusion
The aim of the present study was to clinically evaluate a novel add-on device designed 
to monitor continuously patient compliance and CPAP treatment efficacy in OSAS 
patients. The device accuracy was tested against respiratory polygraphy. The results of 
this study suggest that, when correctly connected, NOWAPI® allows a precise measure-
ment of CPAP treatment duration, the main parameter to be monitored on the long-
term to ensure a proper patient follow-up and implementation of adequate patient 
support in case compliance is decreasing.
Although a limited number of patients was included, the study has shown three rel-
evant concerns that were not identified in the bench test and should be corrected in the 
perspective of a larger use at patient homes:
  • First, reverse connection of the device on the patient circuit was possible despite dif-
ferent ends. Although reverse connection did not raise any safety concern (CPAP 
treatment was normally delivered and no adverse event occurred), duration of CPAP 
treatment was in this case inaccurate. A clearer indication of the flow direction is to 
be implemented on the device.
  • Second, AHIs estimated by NOWAPI® slightly differed from the ones obtained by 
interpretation of respiratory polygraphic data, resulting in a AHI underestimation of 
about two events per hour. This finding was expected by the difference in the meth-
ods used to score respiratory events. However, this may lead to miss some patients 
requiring a treatment adjustment and will require a modification of the NOWAPI® 
scoring algorithm.
  • Third, low satisfaction rate of the patients about the traffic-light indicator suggests 
that other means to provide feed-back to the patient about compliance and treat-
ment efficacy are to be considered and the need for a specific focus on CPAP treat-
ment education by the home healthcare provider.
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OSAS is a common condition associated with potentially severe outcomes, to which 
a chronic disease management model should be applied. NOWAPI® could be a useful 
tool to monitor in the early and long term treatment compliance and quality. Because 
patients are treated with many types of CPAPs and interfaces, and because each CPAP 
machine has its own event detection algorithm and report [12], adding-on a monitoring 
device such as NOWAPI® would allow provision of standardized measures and reports 
and it should be i.e. easier to compare a patient to himself when he had tried different 
CPAP machines.
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